Isomorphic Labs, the AI-powered drug discovery company spun out of Google DeepMind, is in advanced discussions to raise more than $2 billion in new funding. The round marks one of the largest biotech AI funding rounds to date, reflecting growing investor interest in applying artificial intelligence to pharmaceutical development.
Nov 12, 2026 · 2 sources
Nov 12, 2026 · 3 sources
Nov 12, 2026 · 2 sources
Nov 11, 2026 · 3 sources
Story comments
Loading comments…